We speculate that the difference in sensitivity between CML and normal progenitors to knockdown of PSMD1 or PSMD3 may be due to differences in posttranslational modifications (PTMs), which could alter peptide targets in malignant versus normal tissues. This evidence concerns the gene PSMD3 and chronic myelogenous leukemia, BCR-ABL1 positive.